Response to "Secondary Exposure of Family Members to Cyclophosphamide After Chemotherapy of Outpatients With Cancer: A Pilot Study".
Near panic around secondary exposure of staff and family members to chemotherapy products is being seen again in spite of the implementation of products and procedures that have been shown to decrease the incidence in these populations. Many erroneous statements surrounding the extent of inadvertent chemotherapy exposure can be found in patient education sheets, in American Cancer Society publications, and, of course, on the Internet.  Therefore, it was with a sense of relief at finally finding a voice of reason that I turned to "Secondary Exposure of Family Members to Cyclophosphamide After Chemotherapy of Outpatients With Cancer: A Pilot Study."  However, I was sadly disappointed for the following reasons. .
D003520:Cyclophosphamide; D005190:Family; D006801:Humans; D009369:Neoplasms; D010045:Outpatients; D010865:Pilot Projects
D003520:Cyclophosphamide
caregivers; cyclophosphamide